| India | Turkey | Austria | |
| Plasmapheresis | from $4,200 | from $1,200 | from $2,000 |
| Therapeutic Apheresis | from $850 | from $1,350 | - |
| Plasma Exchange | from $3,800 | from $3,900 | - |
| DFPP Plasmapheresis | from $1,350 | from $1,850 | - |
No hidden fees – just official clinic prices. Pay at the clinic for Myeloma treatment and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Myeloma treatment and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Myeloma treatment journey.
16 years of experience treating multiple myeloma with expertise in bone marrow transplants – Dr. Badarkhe combines hematology and oncology knowledge for comprehensive care.
Dr. Prakash Pandit specializes in advanced radiation therapies for myeloma at HCG Manavata Cancer Centre.
The doctor is a pediatric hematologist-oncologist with a specialization in bone marrow transplantation. They have extensive experience in treating complex blood disorders and cancers in children. Their clinical focus includes the management of pediatric leukemia, lymphoma, and other hematologic malignancies. The doctor is recognized for their expertise in performing bone marrow transplants and has contributed to advancements in pediatric oncology through clinical research and innovation.
Multiple myeloma is technically categorized as a chronic condition rather than permanently curable. Modern Indian oncology centers achieve deep, long-term remission using advanced therapies. JCI-accredited facilities offer autologous stem cell transplants and quadruplet drug protocols. These methods focus on controlling the disease for a decade or more.
Bookimed Expert Insight: While India is often selected for its low-cost care, the real advantage is the specialization depth in its largest hubs. For example, Global Hospital Chennai is part of a network serving 2,000,000 patients annually and performs over 18,000 procedures. This massive volume means specialists like Dr. Girish Badarkhe at HCG Manavata manage a highly diverse range of myeloma subtypes. High-volume centers often have better access to trials for bispecific antibodies and CAR-T therapies that are not yet widely commercialized.
Patient Consensus: Patients emphasize that `remission` is the realistic goal and warns that treatment is a marathon, not a sprint. Many note that outcomes improve significantly when choosing a dedicated hematology-oncology specialist rather than a general oncologist.
First-line myeloma treatment in Indian hospitals combines proteasome inhibitors with immunotherapy and stem cell transplants. Centers in Delhi and Bengaluru follow National Cancer Grid protocols. These focus on bortezomib-based triplets. Facilities often hold JCI and NABH accreditations to ensure international safety standards.
Bookimed Expert Insight: India is home to the first indigenous CAR T-cell therapy, NexCAR19. While traditional triplets are standard, hospitals like HCG Manavata and Global Hospital Chennai offer deep expertise in managing complex hematology. Dr. Girish Badarkhe at HCG Manavata alone holds significant experience in leukemia and myeloma. Patients should check if their facility utilizes IBM Watson for oncology to further refine drug selection based on genetic data.
Patient Consensus: Patients emphasize that doctors carefully adjust drug combinations based on kidney health and budget. They note it is important to confirm early if the treatment plan leads toward a stem cell transplant.
Active pharmaceutical ingredients for cancer drugs in India are identical to those in the US and Europe. Indian facilities manufacture 40% of US generics. Clinics use the same compounds like bortezomib and lenalidomide within Joint Commission International-accredited hospitals to ensure global safety standards.
Bookimed Expert Insight: India serves as a global manufacturing hub for complex oncology medications. Large networks like Manipal Hospitals and Apollo Hospitals serve over 1,000,000 patients annually. These facilities often implement the same drug protocols for myeloma as Western centers. Hospitals like HCG Manavata Cancer Centre even use technologies like Tomotherapy-H to complement these medications.
Patient Consensus: Patients note that while drug names change, the molecules remain consistent. Many emphasize that treatment success depends heavily on the oncologist’s experience at high-volume centers.
Myeloma treatment in India typically spans 3 to 12 weeks for international patients. Initial workups often begin within days of arrival. Stem cell transplants require the longest stay. High-volume centers like Apollo Hospitals or Manipal Hospitals expedite staging for visiting patients.
Bookimed Expert Insight: Patients arriving at large networks like Manipal Hospitals often bypass diagnostic delays common in smaller clinics. With over 1,900 doctors and 15 locations, these centers use coordinated hematology teams to finalize treatment plans in under 48 hours. This efficiency is critical for myeloma patients who require immediate induction therapy to manage bone pain or kidney issues.
Patient Consensus: Patients note that Indian hospitals frequently repeat baseline laboratory tests even if prior results are provided. It is important to factor in extra days for verify pathology and secure a second hematology opinion before starting intensive cycles.
Indian hospitals support international medical tourists through comprehensive international patient departments. These divisions provide visa invitation letters, remote video consultations, and detailed treatment plans. Facilities like Apollo Hospital Indraprastha and Manipal Hospitals handle over 1,000,000 international patients annually with dedicated logistics teams.
Bookimed Expert Insight: Data shows that India’s largest networks like Manipal and Apollo serve millions of patients because they operate as health systems, not just single buildings. For complex conditions like myeloma, choosing a facility with over 300+ doctors across 40 specialties, such as Artemis Hospitals, ensures that oncology, hematology, and infectious disease teams are integrated into one coordinated international care plan.
Patient Consensus: Patients emphasize that major private hospitals operate like a managed pipeline. They note that having a single coordinator for imaging, labs, and pharmacy helps minimize time away from home during intensive treatment cycles.